# Durvalumab as Consolidation Therapy in Patients With LS-SCLC Following sCRT

> **NCT07309211** · — · RECRUITING · sponsor: **The First Affiliated Hospital with Nanjing Medical University** · enrollment: 25 (estimated)

## Conditions studied

- SCLC, Limited Stage

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT07309211
- **Lead sponsor:** The First Affiliated Hospital with Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-08
- **Primary completion:** 2025-12
- **Final completion:** 2026-12
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2025-12-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07309211

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07309211, "Durvalumab as Consolidation Therapy in Patients With LS-SCLC Following sCRT". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT07309211. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*